{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T01:14:17Z","timestamp":1783300457177,"version":"3.54.6"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T00:00:00Z","timestamp":1778457600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T00:00:00Z","timestamp":1783296000000},"content-version":"vor","delay-in-days":56,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-026-16139-3","type":"journal-article","created":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T01:34:48Z","timestamp":1778463288000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A comparison of cancer treatment protocols in Australia, Canada, and the United Kingdom"],"prefix":"10.1186","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-5661-7977","authenticated-orcid":false,"given":"Jasmine","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8678-7294","authenticated-orcid":false,"given":"Anastasios","family":"Panagiotelis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8946-5079","authenticated-orcid":false,"given":"Rose","family":"Cairns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0505-1363","authenticated-orcid":false,"given":"Nial J.","family":"Wheate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,11]]},"reference":[{"key":"16139_CR1","doi-asserted-by":"crossref","unstructured":"Hanna TP, King WD, Thibodeau S, Jalink M, Paulin GA, Harvey-Jones E et al. Mortality due to cancer treatment delay: systematic review and meta-analysis. Br Med J 2020:m4087.","DOI":"10.1136\/bmj.m4087"},{"issue":"1","key":"16139_CR2","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1002\/ijc.35103","volume":"156","author":"A Forschner","year":"2025","unstructured":"Forschner A, Nanz L, Maczey-Leber Y, Amaral T, Flatz L, Leiter U. Response and outcome of patients with melanoma skin metastases and immune checkpoint inhibition. Int J Cancer. 2025;156(1):145\u201353.","journal-title":"Int J Cancer"},{"issue":"6","key":"16139_CR3","first-page":"394","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394\u2013424.","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"16139_CR4","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/S1470-2045(15)00449-0","volume":"17","author":"S Vogler","year":"2016","unstructured":"Vogler S, Vitry A, Babar. Z-U-D. Cancer drugs in 16 European countries, Australia, and New Zealand: a cross-country price comparison study. Lancet Oncol. 2016;17(1):39\u201347.","journal-title":"Lancet Oncol"},{"key":"16139_CR5","volume-title":"National Optimal Care Pathways Framework","author":"Cancer Australia","year":"2024","unstructured":"Cancer Australia. National Optimal Care Pathways Framework. Canberra: Cancer Australia; 2024."},{"key":"16139_CR6","unstructured":"Cancer Care Ontario. Cancer Care Ontario 2024. Available from: https:\/\/www.cancercareontario.ca\/en.\u00a0 [Cited 30 Jun 2025]."},{"issue":"12","key":"16139_CR7","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1136\/heartjnl-2020-318661","volume":"107","author":"M Garbi","year":"2021","unstructured":"Garbi M. National Institute for Health and Care Excellence clinical guidelines development principles and processes. Heart. 2021;107(12):949\u201353.","journal-title":"Heart"},{"key":"16139_CR8","unstructured":"The Organisation for Economic Co-operation and Development. Health at a Glance 2019: OECD indicators. Paris; 2019."},{"key":"16139_CR9","volume-title":"The Australian health care system","author":"SW Duckett","year":"2015","unstructured":"Duckett SW, Sharon. The Australian health care system. 5 ed. South Melbourne, Victoria: Oxford University Press; 2015.","edition":"5"},{"issue":"9","key":"16139_CR10","doi-asserted-by":"publisher","first-page":"4765","DOI":"10.1002\/cam4.1495","volume":"7","author":"S Djalalov","year":"2018","unstructured":"Djalalov S, Masucci L, Isaranuwatchai W, Evans W, Peter A, Truscott R, et al. Economic evaluation of smoking cessation in Ontario\u2019s regional cancer programs. Cancer Med. 2018;7(9):4765\u201372.","journal-title":"Cancer Med"},{"key":"16139_CR11","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.healthpol.2022.11.011","volume":"127","author":"RW Smith","year":"2023","unstructured":"Smith RW, Jarvis T, Sandhu HS, Pinto AD, O\u2019Neill M, Di Ruggiero E, et al. Centralization and integration of public health systems: perspectives of public health leaders on factors facilitating and impeding COVID-19 responses in three Canadian provinces. Health Policy. 2023;127:19\u201328.","journal-title":"Health Policy"},{"key":"16139_CR12","doi-asserted-by":"publisher","first-page":"g3231","DOI":"10.1136\/bmj.g3231","volume":"348","author":"B Barr","year":"2014","unstructured":"Barr B, Bambra C, Whitehead M. The impact of NHS resource allocation policy on health inequalities in England 2001-11: longitudinal ecological study. Br Med J. 2014;348:g3231.","journal-title":"Br Med J"},{"issue":"4","key":"16139_CR13","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1007\/s13167-010-0050-1","volume":"1","author":"K Grosios","year":"2010","unstructured":"Grosios K, Gahan PB, Burbidge J. Overview of healthcare in the UK. EPMA J. 2010;1(4):529\u201334.","journal-title":"EPMA J"},{"issue":"5","key":"16139_CR14","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1200\/JGO.2016.008250","volume":"3","author":"S Kerr","year":"2017","unstructured":"Kerr S, Jazieh AR, Kerr D. How useful are international treatment guidelines in low- and middle-income countries? J Glob Oncol. 2017;3(5):441\u20133.","journal-title":"J Glob Oncol"},{"issue":"6","key":"16139_CR15","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1016\/S1470-2045(23)00183-3","volume":"24","author":"BE Wilson","year":"2023","unstructured":"Wilson BE, Booth CM, Sullivan R, Aggarwal A, Sengar M, Jacob S, et al. Global application of National Comprehensive Cancer Network resource-stratified guidelines for systemic treatment of colon cancer: a population-based, customisable model for cost, demand, and procurement. Lancet Oncol. 2023;24(6):682\u201390.","journal-title":"Lancet Oncol"},{"issue":"3","key":"16139_CR16","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1111\/j.1743-7563.2010.01313.x","volume":"6","author":"C Carrington","year":"2010","unstructured":"Carrington C, Stone L, Koczwara B, Searle C. Development of guidelines for the safe prescribing, dispensing and administration of cancer chemotherapy. Asia Pac J Clin Oncol. 2010;6(3):213\u20139.","journal-title":"Asia Pac J Clin Oncol"},{"issue":"5","key":"16139_CR17","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1016\/S1470-2045(20)30139-X","volume":"21","author":"KN Vokinger","year":"2020","unstructured":"Vokinger KN, Hwang TJ, Grischott T, Reichert S, Tibau A, Rosemann T, et al. Prices and clinical benefit of cancer drugs in the USA and Europe: a cost\u2013benefit analysis. Lancet Oncol. 2020;21(5):664\u201370.","journal-title":"Lancet Oncol"},{"issue":"8","key":"16139_CR18","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1093\/annonc\/mdx110","volume":"28","author":"A Aggarwal","year":"2017","unstructured":"Aggarwal A, Fojo T, Chamberlain C, Davis C, Sullivan R. Do patient access schemes for high-cost cancer drugs deliver value to society?\u2014lessons from the NHS Cancer Drugs Fund. Ann Oncol. 2017;28(8):1738\u201350.","journal-title":"Ann Oncol"},{"issue":"1","key":"16139_CR19","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1186\/s12913-014-0595-0","volume":"14","author":"CS Lim","year":"2014","unstructured":"Lim CS, Lee Y-G, Koh Y, Heo DS. International comparison of the factors influencing reimbursement of targeted anti-cancer drugs. BMC Health Serv Res. 2014;14(1):595.","journal-title":"BMC Health Serv Res"},{"issue":"2","key":"16139_CR20","first-page":"247","volume":"23","author":"Y Zhang","year":"2017","unstructured":"Zhang Y, Hueser HC, Hernandez I. Comparing the approval and coverage decisions of new oncology drugs in the United States and other selected countries. J Manag Care Spec Pharm. 2017;23(2):247\u201354.","journal-title":"J Manag Care Spec Pharm"},{"key":"16139_CR21","volume-title":"RStudio: Integrated Development Environment for R. 2024.04.2\u2009+\u2009764 ed","author":"R Core Team","year":"2024","unstructured":"R Core Team. RStudio: Integrated Development Environment for R. 2024.04.2\u2009+\u2009764 ed. Boston, MA: RStudio, PBC; 2024."},{"key":"16139_CR22","volume-title":"tidyverse: Welcome to the Tidyverse. 2.0.0 ed","author":"H Wickham","year":"2022","unstructured":"Wickham H, Averick M, Bryan J, Chang W, McGowan LD, Fran\u00e7ois R, Grolemund G, Hayes A, Henry L, Hester J, Kuhn M, Pedersen TL, Miller E, Bache SM, M\u00fcller K, Ooms J, Robinson D, Seidel DP, Spinu V, Yutani H. tidyverse: Welcome to the Tidyverse. 2.0.0 ed. Vienna, Austria: The R Foundation; 2022."},{"key":"16139_CR23","unstructured":"eviQ Cancer Treatments Online. Testicular germ cell non-seminoma adjuvant BEP protocol 2019. Available from: https:\/\/www.eviq.org.au\/medical-oncology\/urogenital\/testicular\/319-testicular-germ-cell-non-seminoma-adjuvant-bep.\u00a0 [Cited 1 Apr 2026]."},{"key":"16139_CR24","unstructured":"eviQ Cancer Treatments Online. Testicular germ cell metastatic BEP (bleomycin, etoposide, cisplatin) 2019 [Available from: https:\/\/www.eviq.org.au\/medical-oncology\/urogenital\/testicular\/320-testicular-germ-cell-metastatic-bep-bleomycin."},{"key":"16139_CR25","unstructured":"Cancer Care Ontario. BEP(3D) Regimen 2024. Available from: https:\/\/www.cancercareontario.ca\/en\/drugformulary\/regimens\/monograph\/44951. [Cited 1 Apr 2026]."},{"key":"16139_CR26","unstructured":"Cancer Care Ontario. BEP(5D.) Regimen 2024. Available from: https:\/\/www.cancercareontario.ca\/en\/drugformulary\/regimens\/monograph\/44956. [Cited 1 Apr 2026]."},{"key":"16139_CR27","unstructured":"The Clatterbridge Cancer Centre NHS Foundation Trust. Bleomycin, etoposide and cisplatin (BEP3) germ cell protocol 2024. Available from: https:\/\/www.clatterbridgecc.nhs.uk\/application\/files\/2417\/7376\/4581\/Belomycin_Etoposide_and_Cisplatin_BEP3_Germ_Cell.pdf. [Cited 1 Apr 2026]."},{"key":"16139_CR28","unstructured":"The Clatterbridge Cancer Centre NHS Foundation Trust. Bleomycin, etoposide and cisplatin (BEP5\u2009\u00b1\u2009EP5) protocol 2024. Available from: https:\/\/www.clatterbridgecc.nhs.uk\/application\/files\/4217\/6794\/8488\/Bleomycin_Etoposide_Cisplatin_BEP5__plus__EP5.pdf. [Cited 1 Apr 2026]."},{"key":"16139_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/annonc\/mdv299","volume":"26","author":"G Pentheroudakis","year":"2015","unstructured":"Pentheroudakis G, Cardoso F, Arnold D, Sessa C, Peters S, Horwich A, et al. The ESMO guideline strategy: an identity statement and reflections on improvement. Ann Oncol. 2015;26:1\u20137.","journal-title":"Ann Oncol"},{"key":"16139_CR30","unstructured":"ESMO. European Society for Medical Oncology: European Society for Medical Oncology. 2025. Available from: https:\/\/www.esmo.org\/.\u00a0 [Cited 27 Jun 2025]."},{"key":"16139_CR31","unstructured":"NCCN. National Comprehensive Cancer Network Pennsylvania National Comprehensive Cancer Network. 2025. Available from: https:\/\/www.nccn.org\/. [Cited 27 Jun 2025]."},{"issue":"10","key":"16139_CR32","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1038\/s41416-020-0770-5","volume":"122","author":"JC Chisholm","year":"2020","unstructured":"Chisholm JC, Carceller F, Marshall LV. Tumour-agnostic drugs in paediatric cancers. Br J Cancer. 2020;122(10):1425\u20137.","journal-title":"Br J Cancer"},{"key":"16139_CR33","unstructured":"Bayer Australia. Precision Medicine Funded for Australians with Rare Cancers: Bayer Australia; 2024. Available from: https:\/\/www.bayer.com.au\/en\/precision-medicine-funded. [Cited 4 Jul 2025]."},{"issue":"1","key":"16139_CR34","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1586\/17512433.2015.990380","volume":"8","author":"B Godman","year":"2015","unstructured":"Godman B, Malmstr\u00f6m RE, Diogene E, Gray A, Jayathissa S, Timoney A, et al. Are new models needed to optimize the utilization of new medicines to sustain healthcare systems? Expert Rev Clin Pharmacol. 2015;8(1):77\u201394.","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"1","key":"16139_CR35","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/1750-1172-6-42","volume":"6","author":"S Simoens","year":"2011","unstructured":"Simoens S. Pricing and reimbursement of orphan drugs: the need for more transparency. Orphanet J Rare Dis. 2011;6(1):42.","journal-title":"Orphanet J Rare Dis"},{"issue":"8","key":"16139_CR36","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1007\/s00432-024-05889-x","volume":"150","author":"J Lee","year":"2024","unstructured":"Lee J, Panagiotelis A, Cairns R, Wheate NJ. An analysis of the trends in the usage of Pharmaceutical Benefits Scheme-subsidised cancer drugs in Australia from 2012 to 2022. J Cancer Res Clin Oncol. 2024;150(8):375.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"4","key":"16139_CR37","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1002\/cpt.430","volume":"100","author":"BP Smith","year":"2016","unstructured":"Smith BP. Challenges and opportunities in rare disease drug development. Clin Pharmacol Ther. 2016;100(4):312\u20134.","journal-title":"Clin Pharmacol Ther"},{"key":"16139_CR38","doi-asserted-by":"publisher","first-page":"j4530","DOI":"10.1136\/bmj.j4530","volume":"359","author":"C Davis","year":"2017","unstructured":"Davis C, Naci H, Gurpinar E, Poplavska E, Pinto A, Aggarwal A. Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009-13. Br Med J. 2017;359:j4530.","journal-title":"Br Med J"},{"issue":"12","key":"16139_CR39","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1002\/ijc.35070","volume":"155","author":"Q Zhang","year":"2024","unstructured":"Zhang Q, Chen K, Yu X, Fan Y. Spotlight on the treatment of non-small cell lung cancer with rare genetic alterations and brain metastasis: Current status and future perspectives. Int J Cancer. 2024;155(12):2117\u201328.","journal-title":"Int J Cancer"},{"issue":"17","key":"16139_CR40","doi-asserted-by":"publisher","first-page":"18133","DOI":"10.1002\/cam4.6375","volume":"12","author":"M Salek","year":"2023","unstructured":"Salek M, Silverstein A, Tilly A, Gassant PY, Gunasekera S, Hordofa DF, et al. Factors influencing treatment decision-making for cancer patients in low\u2010 and middle\u2010income countries: A scoping review. Cancer Med. 2023;12(17):18133\u201352.","journal-title":"Cancer Med"},{"issue":"1","key":"16139_CR41","doi-asserted-by":"publisher","first-page":"e000258","DOI":"10.1136\/esmoopen-2017-000258","volume":"3","author":"E Pallari","year":"2018","unstructured":"Pallari E, Fox AW, Lewison G. Differential research impact in cancer practice guidelines\u2019 evidence base: lessons from ESMO, NICE and SIGN. ESMO Open. 2018;3(1):e000258.","journal-title":"ESMO Open"},{"key":"16139_CR42","unstructured":"NHS England. Chemotherapy dose banding 2022. Available from: https:\/\/www.england.nhs.uk\/commissioning\/spec-services\/npc-crg\/group-b\/b02\/chemotherapy-dose-banding\/. [Cited 27 Jun 2025]."},{"issue":"4","key":"16139_CR43","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1007\/s40262-025-01492-6","volume":"64","author":"MP Kicken","year":"2025","unstructured":"Kicken MP, Deenen MJ, Van Der Wekken AJ, Van Den Borne BEEM, Van Den Heuvel MM, Ter Heine R. Opportunities for Precision Dosing of Cytotoxic Drugs in Non-Small Cell Lung Cancer: Bridging the Gap in Precision Medicine. Clin Pharmacokinet. 2025;64(4):511\u201331.","journal-title":"Clin Pharmacokinet"},{"key":"16139_CR44","doi-asserted-by":"crossref","unstructured":"Koelsch N, Manjili MH. Moving beyond cytotoxicity in cancer immunotherapy: embracing tumor microenvironment remodeling for durable control. Br J Cancer. 2025.","DOI":"10.1038\/s41416-025-03133-y"},{"key":"16139_CR45","doi-asserted-by":"crossref","unstructured":"Tannock IF, Hickman JA. Limits to personalized cancer medicine. N Engl J Med. 375(13):1289\u201394.","DOI":"10.1056\/NEJMsb1607705"},{"issue":"6","key":"16139_CR46","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1111\/cts.12567","volume":"11","author":"M Ovacik","year":"2018","unstructured":"Ovacik M, Lin K. Tutorial on Monoclonal Antibody Pharmacokinetics and Its Considerations in Early Development. Clin Transl Sci. 2018;11(6):540\u201352.","journal-title":"Clin Transl Sci"},{"issue":"2","key":"16139_CR47","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1111\/cts.12597","volume":"12","author":"D Leipold","year":"2019","unstructured":"Leipold D, Prabhu S. Pharmacokinetic and Pharmacodynamic Considerations in the Design of Therapeutic Antibodies. Clin Transl Sci. 2019;12(2):130\u20139.","journal-title":"Clin Transl Sci"},{"issue":"8","key":"16139_CR48","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1093\/annonc\/mdv249","volume":"26","author":"NI Cherny","year":"2015","unstructured":"Cherny NI, Sullivan R, Dafni U, Kerst JM, Sobrero A, Zielinski C, et al. A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS). Ann Oncol. 2015;26(8):1547\u201373.","journal-title":"Ann Oncol"},{"issue":"14","key":"16139_CR49","doi-asserted-by":"publisher","first-page":"1832","DOI":"10.1200\/JCO.2007.10.6583","volume":"25","author":"SM Lichtman","year":"2007","unstructured":"Lichtman SM, Wildiers H, Chatelut E, Steer C, Budman D, Morrison VA, et al. International Society of Geriatric Oncology Chemotherapy Taskforce: evaluation of chemotherapy in older patients\u2013an analysis of the medical literature. J Clin Oncol. 2007;25(14):1832\u201343.","journal-title":"J Clin Oncol"},{"issue":"14","key":"16139_CR50","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.1200\/JCO.2012.42.8375","volume":"30","author":"LE Schnipper","year":"2012","unstructured":"Schnipper LE, Smith TJ, Raghavan D, Blayney DW, Ganz PA, Mulvey TM, et al. American Society of Clinical Oncology identifies five key opportunities to improve care and reduce costs: the top five list for oncology. J Clin Oncol. 2012;30(14):1715\u201324.","journal-title":"J Clin Oncol"},{"issue":"44","key":"16139_CR51","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1093\/jncimonographs\/lgs008","volume":"2012","author":"SH Taplin","year":"2012","unstructured":"Taplin SH, Anhang Price R, Edwards HM, Foster MK, Breslau ES, Chollette V, et al. Introduction: Understanding and influencing multilevel factors across the cancer care continuum. J Natl Cancer Inst. 2012;2012(44):2\u201310.","journal-title":"J Natl Cancer Inst"},{"issue":"8","key":"16139_CR52","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1016\/S1470-2045(17)30445-X","volume":"18","author":"G Gatta","year":"2017","unstructured":"Gatta G, Capocaccia R, Botta L, Mallone S, De Angelis R, Ardanaz E, et al. Burden and centralised treatment in Europe of rare tumours: results of RARECAREnet-a population-based study. Lancet Oncol. 2017;18(8):1022\u201339.","journal-title":"Lancet Oncol"},{"key":"16139_CR53","unstructured":"European Medicines Agency. Annual Report 2022: The European Medicines. Agency\u2019s contribution to science, medicines and health in 2022. Amsterdam, Netherlands; 2023."}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-026-16139-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16139-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16139-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T00:17:00Z","timestamp":1783297020000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-026-16139-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,11]]},"references-count":53,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["16139"],"URL":"https:\/\/doi.org\/10.1186\/s12885-026-16139-3","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,11]]},"assertion":[{"value":"24 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Approval by a Human Research Ethics Committee was not required for our analysis of publicly available data.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"816"}}